<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04837001</url>
  </required_header>
  <id_info>
    <org_study_id>FDY-5301-302</org_study_id>
    <secondary_id>2021-001924-16</secondary_id>
    <nct_id>NCT04837001</nct_id>
  </id_info>
  <brief_title>Evaluation in STEMI Patients Using FDY-5301</brief_title>
  <acronym>IOCYTE AMI-3</acronym>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intravenous FDY 5301 in Patients With an Anterior ST-Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faraday Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Faraday Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effect of FDY-5301 on cardiovascular mortality and acute heart failure events&#xD;
      in subjects with an anterior STEMI undergoing pPCI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of FDY-5301 compared to&#xD;
      placebo on cardiovascular clinical outcomes in subjects with an anterior ST-elevation&#xD;
      myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI).&#xD;
&#xD;
      The study is designed as a randomized double-blind parallel-group comparison of FDY-5301 and&#xD;
      placebo. Inclusion and exclusion criteria have been designed to ensure a broad population&#xD;
      including seriously ill patients, with or without prior myocardial infarction or coronary&#xD;
      artery bypass graft. Demonstration of efficacy in the anterior STEMI population will&#xD;
      translate to all STEMIs agnostic of anatomical location, as the pathophysiology and&#xD;
      pharmacology are highly likely to translate from anterior STEMIs to non-anterior STEMIs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 15, 2022</start_date>
  <completion_date type="Anticipated">July 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All subjects who fulfill all study eligibility criteria will be randomized and dosed with study drug or placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of either cardiovascular mortality or acute heart failure</measure>
    <time_frame>Through Month 12</time_frame>
    <description>The proportion of subjects who experience either cardiovascular mortality or an acute heart failure event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality or acute heart failure</measure>
    <time_frame>Through Month 12</time_frame>
    <description>The proportion of subjects who experience either all-cause mortality or an acute heart failure event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>Through Month 12</time_frame>
    <description>The total number of cardiovascular events defined as cardiovascular mortality and acute heart failure events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other non-fatal cardiovascular morbidity</measure>
    <time_frame>Through Month 12</time_frame>
    <description>The proportion of subjects who experience other non-fatal cardiovascular morbidity such as CVA, ventricular aneurysm/hemorrhage, recurrent myocardial infarction, or persistent arrhythmia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum troponin T</measure>
    <time_frame>Day 3</time_frame>
    <description>Serum troponin T</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2300</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <condition>STEMI</condition>
  <condition>Percutaneous Coronary Revascularization</condition>
  <arm_group>
    <arm_group_label>FDY-5301</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FDY-5301 will be administered as a single IV bolus injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (normal saline) will be administered as a single IV bolus injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FDY-5301</intervention_name>
    <description>FDY-5301 will be administered as a single IV bolus injection.</description>
    <arm_group_label>FDY-5301</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered as a single bolus injection.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Anterior STEMI, based on:&#xD;
&#xD;
             Symptoms of myocardial ischemia (such as chest pain, shortness of breath, jaw pain,&#xD;
             arm pain, diaphoresis, or any anginal equivalent) and&#xD;
&#xD;
             ECG criteria:&#xD;
&#xD;
               -  men &gt; 40 years: ≥ 2 mm of ST elevation in V2 and V3&#xD;
&#xD;
               -  men ≤ 40 years: ≥ 2.5 mm of ST elevation in V2 and V3&#xD;
&#xD;
               -  women ≥ 1.5 mm of ST elevation in V2 and V3&#xD;
&#xD;
          3. Planned primary PCI to occur ≤ 6 hours of onset of first symptoms of myocardial&#xD;
             ischemia&#xD;
&#xD;
          4. Institutional Review Board (IRB) / Independent Ethics Committee (IEC) approved consent&#xD;
             obtained for study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Life expectancy of less than 1 year due to non-cardiac pathology&#xD;
&#xD;
          2. Known thyroid disease or thyroid disorder, including subjects on thyroid hormone&#xD;
             replacement therapy at the time of randomization&#xD;
&#xD;
          3. Known allergy to iodine&#xD;
&#xD;
          4. Renal disease requiring dialysis&#xD;
&#xD;
          5. Women who are pregnant or breastfeeding. Women of reproductive potential must have a&#xD;
             negative pregnancy test prior to randomization&#xD;
&#xD;
          6. Body weight &gt; 140 kg (or 309 lbs)&#xD;
&#xD;
          7. Use of thrombolytic therapy as treatment for the index STEMI event&#xD;
&#xD;
          8. Use of investigational drugs or devices 30 days prior to randomization&#xD;
&#xD;
          9. Any clinically significant abnormality identified prior to randomization that in the&#xD;
             judgment of the Investigator or Sponsor would preclude safe completion of the study,&#xD;
             or confound the anticipated benefit of FDY-5301&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christian Buhagiar</last_name>
    <phone>206-492-5310</phone>
    <email>info@faradaypharma.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 6, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

